- Company
- Will the flu vaccine market rebound?
- by May 2, 2022 06:03am
- As the obligation to wear outdoor masks is lifted from today, attention is being paid to whether there will be a new change in the influenza vaccine market this year. This is because the importance of flu vaccination increases as the possibility of flu infection, especially COVID-19, increases if taking off the mask. Prime Minister Kim Bu-
- Company
- Rozlytrek can be prescribed with reimb in Korea
- by Eo, Yun-Ho May 2, 2022 06:02am
- The tumor-agnostic drug Rozlytrek may now be prescribed at general hospitals in Korea. According to industry sources, Roche Korea’s NTRK(Neurotrophic tyrosine receptor kinase) targeted anticancer therapy Rozyltrek (entrectinib) has passed the drug committees of medical institutions including the Seoul National University Hospital, Sever
- Company
- Daewoong - AZ Targets Asian Market with Crezet
- by Chon, Seung-Hyun May 2, 2022 06:02am
- Daewoong Pharmaceutical, along with AstraZeneca Korea, is pushing to target the Asian market for Crezet, a hyperlipidemia treatment. Daewoong Pharmaceutical signed a cooperative contract with AstraZeneca Korea on the 27th and agreed to push for Crezet exports to Indonesia, Thailand, the Philippines, and Malaysia. Crezet is a composite of R
- Company
- The size of the DPP-4 diabetes Rx market is decreasing
- by Apr 29, 2022 05:42am
- DPP-4 inhibitor-based drugs used to treat diabetes continue to decline this year. Sales of prescriptions for major products such as Janumet, Trajenta, and Galvus fell one after another. LG Chem's Zemimet, which rose to No. 1 in the market last year, is the only top-tier item to grow, recording 23 billion won in quarterly prescriptions. Acc
- Company
- Zolgensma makes one step towards reimbursement
- by Eo, Yun-Ho Apr 29, 2022 05:42am
- Discussions on the reimbursement of ‘Zolgensma’ are finally making progress. According to industry sources, reimbursement of Novartis Korea’s Spinal Muscular Atrophy (SMA) treatment Zolgensma (onasemnogene abeparvovec-xioi) will be deliberated by the Drug Reimbursement Evaluation Committee of the National Health Insurance Service in coming
- Company
- Sale of Atozet generics exceeds its orignial in 1 year
- by Kim, Jin-Gu Apr 29, 2022 05:42am
- The combination drug market for dyslipidemia treatment using the atorvastatin+ ezetimibe combination has increased twofold with the sudden growth of its generics. Moreover, the market share of the generics exceeded that of the original in Q1 of this year. The rapid expansion of the market last year is interpreted to be due to more than 100 co
- Company
- LG Chem will jointly sell Nesp & Regpara with Kyowa Kirin
- by Kim, Jin-Gu Apr 29, 2022 05:41am
- LG Chem announced on the 28th that it has signed a contract with Kyowa Kirin Korea to jointly sell two drugs, Nesp(Darbepoetin Alfa) and Regpara (Cinacalcet Hydrochloride)' in Korea. LG Chem is in charge of sales at the clinics level, and Kyowa Kirin Korea is in charge of sales at the general hospital level. Nesp is a continuous hematopoietic
- Company
- Immunotherapy Opdivo reattempts reimb in gastric cancer
- by Eo, Yun-Ho Apr 28, 2022 06:07am
- The cancer immunotherapy Opidvo is again attempting to receive insurance benefits for its gastric cancer indication. According to industry sources, ONO Pharma Korea and BMS Korea’s PD-1 inhibitor immunotherapy drug ‘Opdivo (nivolumab)’ will be presented for deliberation by the Cancer Disease Deliberation Committee of the Health Insuran
- Company
- Sales of SGLT-2 diabetes drugs increased by 15%
- by Apr 28, 2022 06:06am
- The SGLT-2 inhibitor market, which surpassed 150 billion won in annual prescriptions last year, also grew 15% in the first quarter, surpassing 40 billion won in quarterly prescriptions. single and combination drugs have grown evenly. According to UBIST, a pharmaceutical market research firm, on the 28th, the total amount of outpatient prescri
- Company
- Who will follow SK Bio with its homegrown COVID-19 vaccine?
- by Kim, Jin-Gu Apr 28, 2022 06:06am
- The marketing authorization for SK Bioscience’s homegrown COVID-19 vaccine 'GBP510' is nearing approval. If the drug is approved within the first half of the year as planned, GBP510 will become the first homegrown vaccine to be ever approved. With the developer of the first vaccine set, who will be the No.2 and No.3 in line is gaining
